Abstract: The disclosure relates to a method for improving the selectivity of a membrane, specifically of a membrane comprising a blend of i) a polysulfone, polyethersulfone or polyarylethersulfone and ii) polyvinylpyrrolidone, characterized in that the membrane is coated with polydopamine and heparin in a one-step or two-step reaction or by in situ modification with polydopamine followed by coating with heparin. The disclosure further relates to a process for producing such modified membranes having an improved selectivity, and to a filtration/diffusion device comprising the membrane which can be used, for example, in hemodialysis applications.

Abstract: The present disclosure relates to an anticoagulant-coated microporous hollow fiber membrane showing reduced thrombogenicity. The disclosure further relates to a method for producing the membrane and a filtration and/or diffusion device comprising the membrane.

Abstract: The present disclosure relates to devices for the extracorporeal treatment of a patient having a complement factor related disease. The devices are adapted to remove said complement factors from the blood or blood plasma of a patient in need. The disclosure further relates to extracorporeal circuits comprising such devices and methods for the treatment of a patient suffering from a complement factor related disease.

Abstract: The present disclosure relates to a hemodialysis membrane for the treatment of hemolytic events, especially acute episodes of hemolysis which lead to elevated levels of plasma free hemoglobin. The present disclosure further relates to methods of removing hemoglobin from the blood of patients undergoing a hemolytic event. The treatment and method encompasses using a hemodialysis membrane which is characterized in that it comprises at least one hydrophobic polymer and at least one hydrophilic polymer and in that it has a MWRO of between 15 and 20 kD and a MWCO of between 170-320 kD, or, in the alternative, has a MWRO of between 9 and 14 kD and a MWCO of between 55 kD and 130 kD.

Abstract: The present disclosure relates to a hemodialysis membrane for the treatment of hemolytic events, especially acute episodes of hemolysis which lead to elevated levels of plasma free hemoglobin. The present disclosure further relates to methods of removing hemoglobin from the blood of patients undergoing a hemolytic event. The treatment and method encompasses using a hemodialysis membrane which is characterized in that it comprises at least one hydrophobic polymer and at least one hydrophilic polymer and in that it has a MWRO of between 15 and 20 kD and a MWCO of between 170-320 kD, or, in the alternative, has a MWRO of between 9 and 14 kD and a MWCO of between 55 kD and 130 kD.

Abstract: The present invention relates to aptazyme sensor devices comprising, in addition to the aptamer, ribozyme and communication components, a competitive inhibitory component with a metal nanoparticle or a competitive inhibitory and signalling component with a metal nanoparticle and a label, such that the enzymatic activity of the ribozyme is inhibited as long as the inhibitory or the inhibitory and signalling component is bound to the substrate binding site of the ribozyme. The aptazyme sensor devices of the invention have increased shelf-life and are suitable for the parallel detection of different ligands by using an array of aptazyme sensor devices utilizing inhibitory and inhibitory and signalling components with different metal nanoparticles. The present invention furthermore relates to the post-synthetic chemical modification of the aptamer component for avoiding unspecific binding.

Abstract: The present invention relates to aptazyme sensor devices comprising, in addition to the aptamer, ribozyme and communication components, a competitive inhibitory component with a metal nanoparticle or a competitive inhibitory and signalling component with a metal nanoparticle and a label, such that the enzymatic activity of the ribozyme is inhibited as long as the inhibitory or the inhibitory and signalling component is bound to the substrate binding site of the ribozyme. The aptazyme sensor devices of the invention have increased shelf-life and are suitable for the parallel detection of different ligands by using an array of aptazyme sensor devices utilizing inhibitory and inhibitory and signalling components with different metal nanoparticles. The present invention furthermore relates to the post-synthetic chemical modification of the aptamer component for avoiding unspecific binding.

Abstract: A method of derivatising an analyte for subsequent detection through a nucleic acid based sensor and a sensor based thereon.

Abstract: The present invention relates to a sensor for thiol analytes, to a sensor array and to a method of detecting thiol analytes using said sensor.

Abstract: The present invention relates to a sensor for thiol analytes, to a sensor array and to a method of detecting thiol analytes using said sensor.

Abstract: A method of derivatising an analyte for subsequent detection through a nucleic acid based sensor and a sensor based thereon.

Abstract: The present invention relates to a sensor for detecting an analyte, to a sensor array, and to a method of detecting an analyte using the sensor of the invention.